Please login to the form below

Not currently logged in
Email:
Password:

bone disease

This page shows the latest bone disease news and features for those working in and with pharma, biotech and healthcare.

Lilly's abemaciclib data leaves potential uncertain

Lilly's abemaciclib data leaves potential uncertain

inhibitor as initial treatment because some patients – including those with bone metastases or indolent disease - may do well with endocrine therapy alone. ... In our study, nearly one-third of patients had bone metastases only or a tumour relapsing

Latest news

More from news
Approximately 1 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials.

  • Interview with Roch Doliveux, UCB Interview with Roch Doliveux, UCB

    We mimic the gene defect and apply reverse engineering to build quality bone. ... With anti-sclerostin, for example, we had no bone disease expertise in our development organisation, hence we made a partnership with Amgen.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Bone Therapeutics looks to Pfizer for clinical head Bone Therapeutics looks to Pfizer for clinical head

    Bone Therapeutics looks to Pfizer for clinical head. Guy Heynen has 35 years of industry experience. ... Heynen will support the firm as it progresses its pipeline of regenerative bone disease and orthopaedic therapies through clinical development and

  • Bone Therapeutics looks to Pfizer for clinical head Bone Therapeutics looks to Pfizer for clinical head

    Bone Therapeutics looks to Pfizer for clinical head. Guy Heynen has 35 years of industry experience. ... Heynen will support the firm as it progresses its pipeline of regenerative bone disease and orthopaedic therapies through clinical development and

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics